FDA approves Siltuximab [Sylvant] for rare Castleman’s disease
April 23, 2014 – The U.S. Food and Drug Administration today approved Sylvant (siltuximab) to treat patients with multicentric Castleman’s disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes). MCD causes an abnormal overgrowth of immune …
FDA approves Siltuximab [Sylvant] for rare Castleman’s disease Read more »